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Introduction

26
Diseases caused by Streptococcus pneumoniae are a major health (TIV) deltoid muscle. Three blood samples were taken; at baseline 122 and 1 month after each vaccination (Table 1) . 
148
The safety profile of PCV13 + TIV compared with that of each 149 agent alone was also assessed. The statistical analyses were performed by the sponsor.
247
For the 3 influenza virus subtypes contained in TIV, exact, 2- results, which were computed using the Student's t distribution.
257
Noninferiority was evaluated using the ratio of postvaccination natural log scale which used the Student's t distribution.
263
The fold rises in antibody concentrations from before vaccina- immunogenicity population are presented in Table 2 . IgG analysis 284 was performed in a subset of 605 participants.
285
The safety population (n = 1151) included any participant who 286 received at least 1 dose of the study vaccine (PCV13 + TIV/Placebo 287 group n = 576 and Placebo + TIV/PCV13 group n = 575). 
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394
The data support the conclusion that TIV is sufficiently immuno-395 genic when given concomitantly with PCV13, and that protection 396 against influenza is likely to be clinically indistinguishable from 397 that provided by TIV alone.
398
The IgG GMCs of the 13 serotypes after PCV13 + TIV were uni-
399
formly lower compared with the responses after PCV13 alone.
400
However, the lower responses were still within the 2-fold GMC cri-
401
terion for noninferiority for all pneumococcal serotypes, with the 402 exception of 19F, which was just below the noninferiority margin.
403
The lower immune response observed by concomitant adminis- CI, confidence interval; n, number of participants with an antibody titre that met the prespecified criteria; N, number of participants with a determinate antibody titre for the given concomitant vaccine antigen; PCV13, 13-valent pneumococcal conjugate vaccine; TIV, trivalent inactivated influenza vaccine.
ARTICLE IN PRESS
G Model JVAC 11838 1-8 6 T.F. Schwarz et al. / Vaccine xxx (2011) xxx-xxx
Table 4
Standard hemagglutination inhibition assay GMTs before and after dose 1 and GMFR after dose 1-evaluable immunogenicity population.
TIV antigen vaccine received Predose 1 Postdose 1 Postdose 1/predose 1 GMFR, geometric mean fold rise; GMT, geometric mean titre; n, number of participants with valid and determinate assay results at the given visit; PCV13, 13-valent pneumococcal conjugate vaccine; TIV, trivalent inactivated influenza vaccine.
Table 5
Proportion of participants achieving hemagglutination inhibition assay titres ≥40 after dose 1-evaluable immunogenicity population. N, number of participants with valid and determinate antibody titres for the concomitant vaccine antigen; n, number of participants with an antibody titre that met the prespecified level; PCV13, 13-valent pneumococcal conjugate vaccine; TIV, trivalent inactivated influenza vaccine.
Local reactions at the PCV13 injection site were comparable.
413
Although systemic events were more common after PCV13 + TIV 414 relative to TIV or PCV13 alone, this is probably because of the addi- Table 6 Comparison of pneumococcal IgG GMC 1 month after dose 1 for PCV13 + TIV/Placebo and 1 month after dose 2 for Placebo + TIV/PCV13-evaluable immunogenicity population. • C but <38. 
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